Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA?

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease that results from a hypersensitivity response to Aspergillus fumigatus [1]. It occurs in asthmatic and cystic fibrosis (CF) patients, with a prevalence among CF patients recently estimated at 7.8% [1]. The natural course is characterised by acute exacerbations, which can be life-threatening [2], and progressive, irreversible, lung damage leading to longterm pulmonary fibrosis if the disease is not well controlled [1].